94 related articles for article (PubMed ID: 8669443)
1. Maternal serum markers levels in consecutive pregnancies: a possible genetic predisposition to abnormal levels.
Dar H; Merksamer R; Berdichevsky D; David M
Am J Med Genet; 1996 Jan; 61(2):154-7. PubMed ID: 8669443
[TBL] [Abstract][Full Text] [Related]
2. Preliminary evidence for associations between second-trimester human chorionic gonadotropin and unconjugated oestriol levels with pregnancy outcome in Down syndrome pregnancies.
Benn PA
Prenat Diagn; 1998 Apr; 18(4):319-24. PubMed ID: 9602476
[TBL] [Abstract][Full Text] [Related]
3. Triploidy identified through second-trimester serum screening.
Huang T; Alberman E; Wald N; Summers AM
Prenat Diagn; 2005 Mar; 25(3):229-33. PubMed ID: 15791661
[TBL] [Abstract][Full Text] [Related]
4. Serum triple-marker screening in in vitro fertilization and naturally conceived pregnancies.
Frishman GN; Canick JA; Hogan JW; Hackett RJ; Kellner LH; Saller DN
Obstet Gynecol; 1997 Jul; 90(1):98-101. PubMed ID: 9207822
[TBL] [Abstract][Full Text] [Related]
5. Maternal serum testing for alpha-fetoprotein and human chorionic gonadotropin in high-risk pregnancies.
Jauniaux E; Gulbis B; Tunkel S; Ramsay B; Campbell S; Meuris S
Prenat Diagn; 1996 Dec; 16(12):1129-35. PubMed ID: 8994249
[TBL] [Abstract][Full Text] [Related]
6. Biochemical screening for chromosomal disorders and neural tube defects (NTD): is adjustment of maternal alpha-fetoprotein (AFP) still appropriate in insulin-dependent diabetes mellitus (IDDM)?
Sancken U; Bartels I
Prenat Diagn; 2001 May; 21(5):383-6. PubMed ID: 11360279
[TBL] [Abstract][Full Text] [Related]
7. Second-trimester prenatal screening for Down syndrome and the relationship of maternal serum biochemical markers to pregnancy complications with adverse outcome.
Spencer K
Prenat Diagn; 2000 Aug; 20(8):652-6. PubMed ID: 10951476
[TBL] [Abstract][Full Text] [Related]
8. Unexplained elevated midtrimester maternal serum levels of alpha fetoprotein, human chorionic gonadotropin, or low unconjugated estriol: recurrence risk and association with adverse perinatal outcome.
Wax JR; Lopes AM; Benn PA; Lerer T; Steinfeld JD; Ingardia CJ
J Matern Fetal Med; 2000; 9(3):161-4. PubMed ID: 10914623
[TBL] [Abstract][Full Text] [Related]
9. Detection of maternal serum hCG glycoform variants in the second trimester of pregnancies affected by Down syndrome using a lectin immunoassay.
Talbot JA; Spencer K; Abushoufa RA
Prenat Diagn; 2003 Jan; 23(1):1-5. PubMed ID: 12533803
[TBL] [Abstract][Full Text] [Related]
10. Prenatal screening using maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: two-year experience in a health maintenance organization.
McDuffie RS; Haverkamp AD; Stark CF; Haverkamp C; Barth CK
J Matern Fetal Med; 1996; 5(2):70-3. PubMed ID: 8796771
[TBL] [Abstract][Full Text] [Related]
11. Serum markers for Down's syndrome in relation to number of previous births and maternal age.
Wald NJ; Watt HC
Prenat Diagn; 1996 Aug; 16(8):699-703. PubMed ID: 8878278
[TBL] [Abstract][Full Text] [Related]
12. [Pregnancy complications with abnormal results of biochemical screening for Down syndrome in second trimester and normal fetal karyotype].
Dimitrova V; Chernev T; Vragaleva S; Slŭncheva B; Mikhaĭlova E; Kremenski I; Simeonov E
Akush Ginekol (Sofiia); 2002; 41(6):3-12. PubMed ID: 12577497
[TBL] [Abstract][Full Text] [Related]
13. Inclusion of serum marker measurements from a previous pregnancy improves Down syndrome screening performance.
Larsen SO; Christiansen M; Nørgaard-Pedersen B
Prenat Diagn; 1998 Jul; 18(7):706-12. PubMed ID: 9706652
[TBL] [Abstract][Full Text] [Related]
14. Predicting the result of additional second-trimester markers from a woman's first-trimester marker profile: a new concept in Down syndrome screening.
Maymon R; Cuckle H; Jones R; Reish O; Sharony R; Herman A
Prenat Diagn; 2005 Dec; 25(12):1102-6. PubMed ID: 16231324
[TBL] [Abstract][Full Text] [Related]
15. Second-trimester Down syndrome maternal serum screening in twin pregnancies: impact of chorionicity.
Muller F; Dreux S; Dupoizat H; Uzan S; Dubin MF; Oury JF; Dingeon B; Dommergues M
Prenat Diagn; 2003 Apr; 23(4):331-5. PubMed ID: 12673641
[TBL] [Abstract][Full Text] [Related]
16. Intrahepatic cholestasis of pregnancy has no effect on maternal serum second trimester alpha-fetoprotein and hCG.
Eloranta ML; Heinonen S; Kirkinen P
Acta Obstet Gynecol Scand; 2000 Jul; 79(7):548-52. PubMed ID: 10929953
[TBL] [Abstract][Full Text] [Related]
17. Second trimester prenatal screening for Down syndrome: the associations between the levels of serum markers in successive pregnancies.
Huang T; Boucher K; Summers AM
Prenat Diagn; 2007 Dec; 27(12):1138-42. PubMed ID: 17960787
[TBL] [Abstract][Full Text] [Related]
18. Comparison of urinary hyperglycosylated human chorionic gonadotropin concentration with the serum triple screen for Down syndrome detection in high-risk pregnancies.
Bahado-Singh RO; Oz U; Shahabi S; Mahoney MJ; Baumgarten A; Cole LA
Am J Obstet Gynecol; 2000 Nov; 183(5):1114-8. PubMed ID: 11084551
[TBL] [Abstract][Full Text] [Related]
19. The association of triple-marker test results with adverse pregnancy outcomes in low-risk pregnancies with healthy newborns.
Sayin NC; Canda MT; Ahmet N; Arda S; Süt N; Varol FG
Arch Gynecol Obstet; 2008 Jan; 277(1):47-53. PubMed ID: 17653738
[TBL] [Abstract][Full Text] [Related]
20. [Screening for Down syndrome using triple marker testing in the second trimester of pregnancy].
Lesin J; Skrablin S; Durić K; Suchanek E; Muzinić D; Kalafatić D; Kuvacić I; Zlopasa G; Plavec A
Lijec Vjesn; 2003; 125(3-4):55-60. PubMed ID: 12899094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
